Founded in 2011, Absci is a synthetic biology company based in the United States with a core mission to streamline biologic drug discovery and development. The company leverages an integrated drug creation platform that combines synthetic biology and artificial intelligence to accelerate the process of bringing new drugs to market. Absci's innovative approach aims to transform the pharmaceutical industry by making drug development faster, more efficient, and cost-effective.
Absci has attracted notable investors and industry leaders, including prominent venture capital firms and biotech experts. The company has achieved significant milestones, such as successful partnerships with major pharmaceutical companies and advancements in AI-driven drug discovery. Absci's impact on the biotech sector is marked by its potential to revolutionize how new therapeutics are developed, ultimately improving patient outcomes and addressing unmet medical needs.
